Ascentage Pharma Group International (AAPG) Competitors

Ascentage Pharma Group International logo
$12.01 -0.43 (-3.46%)
Closing price 11/20/2026 03:57 PM Eastern
Extended Trading
$11.66 -0.35 (-2.87%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AAPG vs. GRAL, IONS, EWTX, CRSP, and TNGX

Should you buy Ascentage Pharma Group International stock or one of its competitors? Ascentage Pharma Group International's main competitors and comparable companies include GRAIL (GRAL), Ionis Pharmaceuticals (IONS), Edgewise Therapeutics (EWTX), CRISPR Therapeutics (CRSP), and Tango Therapeutics (TNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascentage Pharma Group International compare to GRAIL?

Ascentage Pharma Group International (NASDAQ:AAPG) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Ascentage Pharma Group International presently has a consensus price target of $43.44, indicating a potential upside of 261.74%. GRAIL has a consensus price target of $128.80, indicating a potential upside of 29.96%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, research analysts clearly believe Ascentage Pharma Group International is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.15
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

Ascentage Pharma Group International has higher earnings, but lower revenue than GRAIL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M13.71-$177.71MN/AN/A
GRAIL$147.17M30.28-$408.35M-$9.50N/A

In the previous week, GRAIL had 4 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 9 mentions for GRAIL and 5 mentions for Ascentage Pharma Group International. GRAIL's average media sentiment score of 0.74 beat Ascentage Pharma Group International's score of 0.52 indicating that GRAIL is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GRAIL
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ascentage Pharma Group International has a net margin of 0.00% compared to GRAIL's net margin of -243.80%. Ascentage Pharma Group International's return on equity of 0.00% beat GRAIL's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
GRAIL -243.80%-16.13%-14.38%

Ascentage Pharma Group International has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, GRAIL has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market.

Summary

Ascentage Pharma Group International beats GRAIL on 8 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Ascentage Pharma Group International (NASDAQ:AAPG) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

In the previous week, Ionis Pharmaceuticals had 20 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 25 mentions for Ionis Pharmaceuticals and 5 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.52 beat Ionis Pharmaceuticals' score of -0.02 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
4 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ascentage Pharma Group International
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ionis Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ascentage Pharma Group International has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -56.98%. Ascentage Pharma Group International's return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-56.98% -120.62% -16.99%
Ascentage Pharma Group International N/A N/A N/A

Ascentage Pharma Group International has lower revenue, but higher earnings than Ionis Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$944M4.69-$381.39M-$3.32N/A
Ascentage Pharma Group International$82.10M13.71-$177.71MN/AN/A

Ionis Pharmaceuticals presently has a consensus target price of $75.00, indicating a potential upside of 182.14%. Ascentage Pharma Group International has a consensus target price of $43.44, indicating a potential upside of 261.74%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Ionis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.78
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.15

Summary

Ascentage Pharma Group International beats Ionis Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Edgewise Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Ascentage Pharma Group International's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Edgewise Therapeutics N/A -7.15%-6.65%

Ascentage Pharma Group International has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Edgewise Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M13.71-$177.71MN/AN/A
Edgewise TherapeuticsN/AN/A-$167.79M$8.194.87

In the previous week, Edgewise Therapeutics had 7 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 12 mentions for Edgewise Therapeutics and 5 mentions for Ascentage Pharma Group International. Edgewise Therapeutics' average media sentiment score of 0.77 beat Ascentage Pharma Group International's score of 0.52 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Edgewise Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ascentage Pharma Group International presently has a consensus price target of $43.44, indicating a potential upside of 261.74%. Edgewise Therapeutics has a consensus price target of $53.58, indicating a potential upside of 34.40%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascentage Pharma Group International is more favorable than Edgewise Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.15
Edgewise Therapeutics
2 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.58

Summary

Ascentage Pharma Group International beats Edgewise Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Ascentage Pharma Group International (NASDAQ:AAPG) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

CRISPR Therapeutics currently has a consensus price target of $72.93, indicating a potential upside of 86.35%. Ascentage Pharma Group International has a consensus price target of $43.44, indicating a potential upside of 261.74%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.15

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 5 mentions for Ascentage Pharma Group International. CRISPR Therapeutics' average media sentiment score of 0.66 beat Ascentage Pharma Group International's score of 0.52 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive
Ascentage Pharma Group International
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ascentage Pharma Group International has higher revenue and earnings than CRISPR Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$3.51M1,081.51-$581.60M-$4.74N/A
Ascentage Pharma Group International$82.10M13.71-$177.71MN/AN/A

CRISPR Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Ascentage Pharma Group International has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,812.07%. Ascentage Pharma Group International's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-1,812.07% -25.59% -17.89%
Ascentage Pharma Group International N/A N/A N/A

Summary

Ascentage Pharma Group International beats CRISPR Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Tango Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Tango Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M13.71-$177.71MN/AN/A
Tango Therapeutics$62.38M59.03-$101.59M-$1.37N/A

In the previous week, Tango Therapeutics had 5 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 10 mentions for Tango Therapeutics and 5 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.52 beat Tango Therapeutics' score of 0.38 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tango Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ascentage Pharma Group International's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Tango Therapeutics N/A -30.34%-28.28%

79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ascentage Pharma Group International has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Ascentage Pharma Group International presently has a consensus target price of $43.44, suggesting a potential upside of 261.74%. Tango Therapeutics has a consensus target price of $48.17, suggesting a potential upside of 121.66%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascentage Pharma Group International is more favorable than Tango Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.15
Tango Therapeutics
2 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.65

Summary

Ascentage Pharma Group International and Tango Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AAPG vs. The Competition

MetricAscentage Pharma Group InternationalBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.12B$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.69%
P/E RatioN/A23.0732.5628.72
Price / Sales1.7515.358.005.34
Price / CashN/A21.9220.2520.77
Price / Book5.894.124.343.51
Net Income-$177.71M-$24.08M$3.51B$394.12M
7 Day Performance-17.85%-9.85%-8.07%-8.97%
1 Month Performance-19.50%-12.77%-10.29%-11.61%
1 Year Performance-60.80%-7.99%-4.70%-11.21%

Ascentage Pharma Group International Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AAPG
Ascentage Pharma Group International
4.5597 of 5 stars
$12.01
-3.5%
$43.44
+261.7%
-60.8%$1.12B$642.64MN/A767
GRAL
GRAIL
2.8567 of 5 stars
$99.11
-5.5%
$128.80
+30.0%
+5.9%$4.46B$147.17MN/A910
IONS
Ionis Pharmaceuticals
2.8855 of 5 stars
$26.58
-2.3%
$75.00
+182.1%
-65.1%$4.43B$944MN/A1,402
EWTX
Edgewise Therapeutics
3.2541 of 5 stars
$39.87
-3.2%
$53.58
+34.4%
+75.9%$4.36BN/A4.87133
CRSP
CRISPR Therapeutics
2.8048 of 5 stars
$39.14
+0.5%
$72.93
+86.4%
-22.1%$3.80B$3.51MN/A393

Related Companies and Tools


This page (NASDAQ:AAPG) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners